27
Participants
Start Date
December 31, 2004
Primary Completion Date
November 30, 2007
Study Completion Date
December 31, 2007
cetuximab
Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
molecular diagnostic method
Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
immunologic technique
Peripheral Blood Mononuclear Cells (PBMC)
laboratory biomarker analysis
Cetuximab Pharmacodynamics
University of California Davis Cancer Center, Sacramento
National Cancer Institute (NCI)
NIH
University of California, Davis
OTHER